Waters Unveils Cyclic IMS P20 MS: The New Benchmark in Structural and Spatial Omics
Rhea-AI Summary
Waters (NYSE: WAT) launched the Cyclic IMS P20 Mass Spectrometer, a high-resolution structural and spatial omics platform unveiled at ASMS 2026. It combines multipass Cyclic Ion Mobility Spectrometry with advanced fragmentation, probing, and imaging to enhance early disease signal detection and biotherapeutic development.
The system delivers >10x higher MS/MS sensitivity than its predecessor, a >50% extended upper mass range to >100 kDa, and integrates MALDI XS and DESI XS imaging. Global availability is expected from September 2026.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
WAT gained 4.61% while close peers were mixed with modest moves (e.g., ILMN +1.88%, MTD +1.53%, DGX -0.86%, LH -0.97%, PKI flat). No broad sector rotation is evident, pointing to a stock‑specific reaction to the new platform launch.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 18 | Conference participation | Neutral | +1.2% | Announcement of CEO fireside chat at Jefferies Global Healthcare Conference. |
| May 05 | Earnings results | Positive | +13.5% | Q1 2026 revenue beat guidance and company raised full‑year growth and EPS outlook. |
| Apr 20 | Earnings call schedule | Neutral | -0.1% | Set date and time for Q1 2026 earnings release and conference call. |
| Apr 14 | Product launch | Positive | +1.9% | Introduced omniDAWN MALS detector offering faster runs and extended sizing. |
| Apr 08 | FDA clearance | Positive | +3.6% | FDA cleared Onclarity HPV self‑collection kit and approved at‑home HPV assay. |
Recent product and regulatory milestones have generally seen positive price reactions, especially when tied to strong financial results or major platform launches.
Over the past few months, Waters reported strong Q1 2026 results with revenue of $1.267 billion and raised full‑year guidance, which coincided with a 13.54% gain after earnings. Product launches, such as the omniDAWN MALS detector on Apr 14, 2026, and FDA clearance of the Onclarity HPV self‑collection kit on Apr 8, 2026, also aligned with positive price moves. The current structural and spatial omics platform launch fits this pattern of innovation‑driven momentum.
Regulatory & Risk Context
Waters has an effective automatic shelf registration on Form S-3ASR filed on 2026-03-16, allowing the company and specified affiliates to issue various securities from time to time. The shelf has seen at least one usage, reflected by a 424B2 filing on 2026-03-19, but no total capacity amount is specified here.
Market Pulse Summary
This announcement introduces the Cyclic IMS P20 Mass Spectrometer, a premium structural and spatial omics platform claiming >10x MS/MS sensitivity and an upper mass range extended by more than 50% to over 100 kDa. It follows other recent product and regulatory milestones and is expected to be available globally beginning September 2026. Investors may monitor how quickly this platform gains adoption alongside Waters’ expanded diagnostics footprint and how it supports future revenue and margin trends.
Key Terms
ion mobility spectrometry technical
mass spectrometer technical
post-translational modifications medical
AI-generated analysis. Not financial advice.
- >10x step-change in MS/MS sensitivity paired with multipass Cyclic™ Ion Mobility Spectrometry (IMS) reveals subtle biological differences for earlier, previously unattainable detection of disease signals.
50% extended upper mass range and comprehensive suite of structural tools advance the development of next-generation biotherapeutics.
- Integrated MALDI XS and DESI XS imaging with high-resolution ion mobility enables direct visualization of molecules in tissue, improving understanding of how disease develops at the cellular level.
"Waters recognizes that advanced tools for structural and spatial omics play a critical role in delivering therapeutic breakthroughs," said James Hallam, Vice President & General Manager, Liquid Chromatography-Mass Spectrometry, Waters Analytical Sciences, Waters Corporation. "With its powerful fusion of capabilities, the Cyclic IMS P20 MS delivers a previously unattainable view into subtle molecular differences, unlocking a new level of understanding of the mechanisms that drive disease and advancing next‑generation discovery."
As researchers pursue larger and more heterogeneous therapeutic targets, analytical workflows need higher sensitivity, higher structural resolution, and easier-to-adopt methods. The Cyclic IMS P20 Mass Spectrometer meets that need with a more than a 10-fold increase in MS/MS sensitivity compared to its predecessor,2 an upper mass range extended by more than
"My lab studies proteins involved in misfoldings that drive human disease, which are notoriously difficult to characterize. We leverage the advanced capabilities of Cyclic IMS P20 MS to perform complex tandem ion mobility experiments on low‑abundance forms of a key molecule involved in the pathogenesis of Type II diabetes," said Kostas Thalassinos, Ph.D., Professor of Mass Spectrometry and Academic Lead, Institute of Structural and Molecular Biology, University College London. "The increase in sensitivity delivered by the new functionality is truly remarkable. It stands to significantly accelerate our analyses, potentially by an order of magnitude, and enables us to probe critical low‑abundance species in far greater detail. These rare molecular populations are essential for delineating the mechanisms that drive human disease."
The Cyclic IMS P20 Mass Spectrometer also brings Matrix-Assisted Laser Desorption/Ionization (MALDI) and Desorption Electrospray Ionization (DESI) imaging sources together in one system, pioneering their combination with advanced multipass cyclic ion mobility and IMS separation to help researchers see more, with greater clarity, directly in their samples. This unique approach broadens coverage across small molecules, lipids, peptides, and proteins, while separating isobaric and stereoisomeric compounds. Additionally, the system delivers multi-dimensional insights that elucidate links between molecular composition and the tissue microenvironment, supporting biomarker identification directly from tissue. These rich, easily-interpreted molecular maps provide increased confidence in lipidomics, drug and metabolite localization, translational research, and other experiments requiring visualization.
The Waters Cyclic IMS P20 Mass Spectrometer will be showcased at ASMS 2026 and is expected to be available globally beginning September 2026. For more information or to request a demo, visit product page.
Additional Resources:
Waters and Cyclic are trademarks of Waters Corporation or its affiliates. All other trademarks are the property of their respective owners.
The P in Cyclic IMS P20 denotes Premium, the highest performance tier from Waters, and 20 reflects the platform's evolution from the SELECT SERIES lineage under Waters' new product naming convention.
About Waters Corporation:
Waters Corporation (NYSE: WAT) is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and service. With a focus on regulated, high-volume testing environments, our innovative portfolio harnesses deep scientific expertise across chemistry, physics, and biology. We collaborate with customers around the world to advance the release of effective, high-quality medicines, ensure the safety of food and water, and drive better patient outcomes by detecting diseases earlier, managing routine infections, and combating antibiotic resistance. Through a shared culture of relentless innovation, our passionate team of ~16,000 colleagues turn scientific challenges into breakthroughs that improve lives worldwide. For more information, please visit www.waters.com/about.
References:
- Imaging modality performance and ion mobility separation examples in tissue; based on internal Waters testing, protocol and sample details on file.
- Up to 10x MS/MS sensitivity comparison (Cyclic IMS P20 vs prior generation instrument) based on internal Waters testing; protocol and sample details on file.
- Upper mass range specification and representative analytes; based on internal Waters testing; see Cyclic IMS P20 Specification sheet.
Contact:
Molly Gluck
Head of External Communications
Waters Corporation
508.498.9732
molly_gluck@waters.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/waters-unveils-cyclic-ims-p20-ms-the-new-benchmark-in-structural-and-spatial-omics-302786888.html
SOURCE Waters Corporation